Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib plus azacitidine and venetoclax for newly diagnosed NPM1-mutated or KMT2A-rearranged AML in adults unfit for intensive chemotherapy
ACTRN12625000964415Phase 3Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Revumenib + azacitidine + venetoclax with Placebo + azacitidine + venetoclax (2 arms). Primary endpoints: Overall survival and Complete remission. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
revumenibazacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12625000964415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000964415.